Screener / SEC EDGAR /CIK 0001428336 /10-K filed Mar 17, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Industrials · Business Services

Healthequity, Inc. HQY

Compare with peers Embed
Earnings releases

Latest results release: Aug 27, 2026

8-K item 2.02, exhibit 99

What HQY's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Sep 2, 2025, HQY reported $0.68 per share under GAAP and $1.08 on its own adjusted basis: the adjusted number is +59% above GAAP.

GAAP EPS $0.17, release Dec 5, 2023: Net income per diluted share of $0.17, compared to net loss per diluted share of $0.02 in Q3 FY23, with non-GAAP net income per diluted share of $0.60, compared to $0.38 in Q3 FY23. Adjusted EPS $0.60, release Dec 5, 2023: Net income per diluted share of $0.17, compared to net loss per diluted share of $0.02 in Q3 FY23, with non-GAAP net income per diluted share of $0.60, compared to $0.38 in Q3 FY23. +253% 2023-12 GAAP EPS $0.64, release Mar 19, 2024: Net income per diluted share of $0.64, compared to net loss per diluted share of $0.31 in FY23, with non-GAAP net income per diluted share of $2.25, compared to $1.36 in FY23. Adjusted EPS $2.25, release Mar 19, 2024: Net income per diluted share of $0.64, compared to net loss per diluted share of $0.31 in FY23, with non-GAAP net income per diluted share of $2.25, compared to $1.36 in FY23. +252% 2024-03 GAAP EPS $0.33, release Jun 3, 2024: Net income per diluted share of $0.33, compared to $0.05 in Q1 FY24, with non- GAAP net income per diluted share of $0.80, compared to $0.50 in Q1 FY24. Adjusted EPS $0.80, release Jun 3, 2024: Net income per diluted share of $0.33, compared to $0.05 in Q1 FY24, with non- GAAP net income per diluted share of $0.80, compared to $0.50 in Q1 FY24. +142% 2024-06 GAAP EPS $0.40, release Sep 3, 2024: Net income per diluted share of $0.40, compared to $0.12 in Q2 FY24, with non- GAAP net income per diluted share of $0.86, compared to $0.53 in Q2 FY24. Adjusted EPS $0.86, release Sep 3, 2024: Net income per diluted share of $0.40, compared to $0.12 in Q2 FY24, with non- GAAP net income per diluted share of $0.86, compared to $0.53 in Q2 FY24. +115% 2024-09 GAAP EPS $0.06, release Dec 9, 2024: Net income per diluted share of $0.06, compared to $0.17 in Q3 FY24, with non- GAAP net income per diluted share of $0.78, compared to $0.60 in Q3 FY24. Adjusted EPS $0.78, release Dec 9, 2024: Net income per diluted share of $0.06, compared to $0.17 in Q3 FY24, with non- GAAP net income per diluted share of $0.78, compared to $0.60 in Q3 FY24. +1200% 2024-12 GAAP EPS $1.09, release Mar 18, 2025: Net income per diluted share of $1.09, an increase of 70% compared to $0.64 in FY24, with non-GAAP net income per diluted share of $3.12, an increase of 39% compared to $2.25 in FY24. Adjusted EPS $3.12, release Mar 18, 2025: Net income per diluted share of $1.09, an increase of 70% compared to $0.64 in FY24, with non-GAAP net income per diluted share of $3.12, an increase of 39% compared to $2.25 in FY24. +186% 2025-03 GAAP EPS $0.61, release Jun 3, 2025: Net income per diluted share of $0.61, an increase of 85% compared to $0.33 in Q1 FY25, with non-GAAP net income per diluted share of $0.97, an increase of 21% compared to $0.80 in Q1 FY25. Adjusted EPS $0.97, release Jun 3, 2025: Net income per diluted share of $0.61, an increase of 85% compared to $0.33 in Q1 FY25, with non-GAAP net income per diluted share of $0.97, an increase of 21% compared to $0.80 in Q1 FY25. +59% 2025-06 GAAP EPS $0.68, release Sep 2, 2025: Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with non-GAAP net income per diluted share of $1.08, an increase of 26% compared to $0.86 in Q2 FY25. Adjusted EPS $1.08, release Sep 2, 2025: Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with non-GAAP net income per diluted share of $1.08, an increase of 26% compared to $0.86 in Q2 FY25. +59% 2025-09
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
Sep 2, 2025 0.68 1.08 +59%
Jun 3, 2025 0.61 0.97 +59%
Mar 18, 2025 1.09 3.12 +186%
Dec 9, 2024 0.06 0.78 +1200%
Sep 3, 2024 0.40 0.86 +115%
Jun 3, 2024 0.33 0.80 +142%
Mar 19, 2024 0.64 2.25 +252%
Dec 5, 2023 0.17 0.60 +253%
The company's words, latest release
Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with non-GAAP net income per diluted share of $1.08, an increase of 26% compared to $0.86 in Q2 FY25. release

What the company says its adjusted numbers leave out:

In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. release Dec 3, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Aug 27, 2026 · EX-99.1

HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results

Open on SEC

HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results Highlights of the second quarter include:

to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share increased

– HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.

"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."

Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.

Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.

Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.

Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.

New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.

Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.

The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program. 1

For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

• Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non- operating items.

• Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.

• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future 2 efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;

• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;

• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;

• the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;

• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;

• the significant competition we face and may face in the future, including from those with greater resources than us;

• our reliance on the availability and performance of our technology and communications systems;

• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;

• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;

• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;

• our reliance on partners and third-party vendors for distribution and important services;

• our ability to develop and implement updated features for our technology platforms and communications systems; and

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward- looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

(in thousands, except par January 31, value) July 31, 2026 2026 ────────────────────────────────────────────────────────────────────────────── -unaudited Assets Current assets Cash and cash $ 256,003 $ 318,927 equivalents Accounts receivable, net of allowance for doubtful accounts of $1,067 and 122,193 123,696 $924 as of July 31, 2026 and January 31, 2026, respectively Prepaid expenses and 82,008 69,658 other current assets Total current 460,204 512,281 assets Property and equipment, 4,823 3,177 net Operating lease 32,874 36,310 right-of-use assets Intangible 1,047,797 1,097,172 assets, net Goodwill 1,648,145 1,648,145 Other assets 77,520 83,247 Total assets $ 3,271,363 $ 3,380,332 Liabilities and stockholders’ equity Current liabilities Accounts $ 8,592 $ 12,159 payable Accrued 37,913 60,392 compensation Accrued 97,300 74,388 liabilities Operating lease 9,970 9,911 liabilities Total current 153,775 156,850 liabilities Long-term liabilities Long-term debt, net of 931,062 957,379 issuance costs Operating lease 29,984 34,190 liabilities, non-current Other long-term 73,999 31,007 liabilities Deferred tax 92,433 93,710 liability Total long-term 1,127,478 1,116,286 liabilities Total 1,281,253 1,273,136 liabilities Commitments and contingencies Stockholders’ equity Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares — — issued and outstanding as of July 31, 2026 and January 31, 2026, respectively Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 8 8 shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively Additional paid-in 1,896,571 1,916,989 capital Accumulated 162,583 195,906 earnings Accumulated other -69,052 -5,707 comprehensive loss Total stockholders’ 1,990,110 2,107,196 equity Total liabilities and $ 3,271,363 $ 3,380,332 stockholders’ equity

(in thousands) Cash flows from Six months ended operating July 31, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 135,062 $ 113,769 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 80,169 77,195 amortization Stock-based 41,616 33,404 compensation Amortization of debt discount and 558 533 issuance costs Amortization of gains on -168 — derivatives Deferred taxes 19,321 30,711 Changes in operating assets and liabilities: Accounts 1,503 6,842 receivable, net Prepaid expenses and other current -12,581 -20,650 and non-current assets Operating lease right-of-use 3,436 3,339 assets Accrued -21,095 -35,032 compensation Accounts payable, accrued liabilities, -13,595 -3,785 and other current liabilities Operating lease liabilities, -4,206 -3,951 non-current Other long-term 3,665 -1,771 liabilities Net cash provided by operating 233,685 200,604 activities Cash flows from investing activities: Capitalized software -30,720 -26,464 development costs Purchases of property and -1,340 -859 equipment Settlement of -7,759 — derivatives, net Net cash used in investing -39,819 -27,323 activities Cash flows from financing activities: Repurchases of -231,054 -125,810 common stock Principal payments -26,875 -50,000 on long-term debt Settlement of client-held funds 480 596 obligation, net Proceeds from exercise of common 659 10,446 stock options Net cash used in financing -256,790 -164,768 activities Increase (decrease) in cash -62,924 8,513 and cash equivalents Beginning cash and 318,927 295,948 cash equivalents Ending cash and $ 256,003 $ 304,461 cash equivalents

(in thousands) Six months ended July Supplemental cash 31, flow data: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Interest expense $ 23,350 $ 28,362 paid in cash Income tax payments, 35,586 6,507 net Supplemental disclosures of non-cash investing and financing activities: Capitalized software development costs included in accounts 3,434 3,380 payable, accrued liabilities, or accrued compensation Purchases of property and equipment 1,294 155 included in accounts payable or accrued liabilities Repurchases of common stock 3,255 1,246 included in accrued liabilities Exercise of common stock options 57 — receivable

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026:

(1) Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.

Outlook for the year ending (in millions) January 31, 2027 ────────────────────────────────────────────────────────────────────────────── Net income $242 - 248 Interest income -7 Interest expense 50 Income tax provision 81 - 83 Depreciation and amortization 54 Amortization of acquired intangible assets 104 Stock-based compensation expense 87 Merger integration expenses 5 Amortization of incremental costs to obtain a 9 contract Costs associated with unused office space 3 Adjusted EBITDA $628 - 636

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. 10 Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

Outlook for the year ending (in millions, except per share data) January 31, 2027 ────────────────────────────────────────────────────────────────────────────── Net income $242 - 248 Income tax provision 81 - 83 Income before income taxes - GAAP 323 - 331 Non-GAAP adjustments: Amortization of acquired intangible assets 104 Stock-based compensation expense 87 Merger integration expenses 5 Costs associated with unused office space 3 Total adjustments to income before income taxes - 199 GAAP Income before income taxes - Non-GAAP 522 - 530 Income tax provision - Non-GAAP (1) 131 - 133 Non-GAAP net income $392 - 398 Diluted weighted-average shares 84 GAAP net income per diluted share $2.88 - 2.96 Non-GAAP net income per diluted share $4.66 - 4.73

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. 11

Term Definition Health Savings Account, which is a financial account through which HSA consumers spend and save long-term for healthcare on a tax-advantaged basis. Consumer-directed benefits offered by employers, including flexible spending and health reimbursement CDB arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits. HSA member Consumers with HSAs that we serve. HSA members’ custodial cash assets held by our federally insured depository partners and our insurance Total HSA Assets company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner. Client Our employer clients. Total Accounts The sum of HSAs and CDBs on our platforms. Deposits held on behalf of our Client-held funds Clients to facilitate administration of our CDBs. Our health plan partners, benefits Network Partner administrators, and retirement plan recordkeepers. Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, Adjusted EBITDA acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, Non-GAAP net income acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. Non-GAAP net income per diluted Calculated by dividing non-GAAP net share income by diluted weighted-average shares outstanding.

Full text with the tables
   HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results    
Highlights of the second quarter include:

• Net income increased
                                                                                
  10%                                                                           
                                                                                
to $65.6 million , and net income margin increased to
                                                                                
  19%                                                                           
                                                                                
from
                                                                                
  18%                                                                           
                                                                                
last year.

• Adjusted EBITDA increased
                                                                                
  11%                                                                           
                                                                                
to $167.0 million , and Adjusted EBITDA margin increased to
                                                                                
  48%                                                                           
                                                                                
from
                                                                                
  46%                                                                           
                                                                                
last year.

• Revenue increased
                                                                                
  8%                                                                            
                                                                                
to $350.7 million .

• Net income per diluted share rose
                                                                                
  15%                                                                           
                                                                                
to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share
increased
                                                                                
  15%                                                                           
                                                                                
to $1.24 .

• Total HSA Assets grew
                                                                                
  14%                                                                           
                                                                                
to $37.9 billion .

• Returned $108.1 million to shareholders through stock repurchases.
                                                                                
  Draper, Utah – August 27, 2026                                                
                                                                                
– HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the
largest independent health savings account ("HSA") custodian by account volume
and a leader in consumer-directed benefits ("CDBs"), today announced financial
results for its second quarter ended July 31, 2026.

"HealthEquity delivered a record-setting second quarter, with record Adjusted
EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets
of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity.
"These results reflect strong execution across the business and the durability
of our model as growth comes from more places, member relationships deepen and
technology-enabled efficiency improves how we serve members and clients. This
momentum gives us confidence to raise fiscal 2027 guidance and enter the second
half focused on scaling efficiently and creating long-term value."
                                                                                
   Second quarter financial results                                             
                                                                                
Revenue for the second quarter ended July 31, 2026 was $350.7 million, an
increase of 8% compared to $325.8 million for the second quarter ended July 31,
2025. Revenue this quarter included: service revenue of $124.4 million,
custodial revenue of $175.9 million, and interchange revenue of $50.4 million.

Net income was $65.6 million, or $0.78 per diluted share, for the second quarter
ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for
the second quarter ended July 31, 2025. Net income margin was 19% for the second
quarter ended July 31, 2026, compared to 18% for the second quarter ended July
31, 2025.

Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the
second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per
diluted share, for the second quarter ended July 31, 2025.

Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026,
an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted
EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31,
2025.
                                                                                
  Account and asset metrics                                                     
                                                                                
New HSAs from sales were 202 thousand, an increase of 24% compared to the second
quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an
increase of 8% year over year, including 0.9 million HSAs with investments, an
increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8
million, including 7.0 million complementary CDBs.

Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year
over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion
of HSA investments. Client-held funds, which are deposits held on behalf of our
Clients to facilitate administration of our CDBs, and from which we generate
custodial revenue, were $0.9 billion as of July 31, 2026.
                                                                                
  Stock repurchase program                                                      
                                                                                
The Company repurchased 1.2 million shares of its common stock for $108.1
million during the second quarter ended July 31, 2026. As of July 31, 2026,
$948.4 million of common stock remained authorized for repurchase under the
stock repurchase program.
                                       1                                        
                                                                                
   Business outlook                                                             
                                                                                
For the fiscal year ending January 31, 2027, management is raising guidance and
now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net
income is between $242 million and $248 million, resulting in net income of
$2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income,
calculated using the method described below, is between $392 million and $398
million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73
(based on an estimated 84 million diluted weighted-average shares outstanding).
Management expects Adjusted EBITDA of $628 million to $636 million.

See “Non-GAAP financial information” below for definitions of our Adjusted
EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial
measures used throughout this release to the most comparable GAAP financial
measures is included with the financial tables at the end of this release.
                                                                                
  Conference call                                                               
                                                                                
HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time)
on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial
results. The conference call will be accessible by dialing 1-833-630-1956, or
1-412-317-1837 for international callers, and referencing conference ID
"HealthEquity." A live audio webcast of the call will be available on the
investor relations section of our website at http://ir.healthequity.com.
                                                                                
   Non-GAAP financial information                                               
                                                                                
To supplement our financial information presented on a GAAP basis, we disclose
non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and
non-GAAP net income per diluted share.

• Adjusted EBITDA is earnings before interest, taxes, depreciation and
amortization, amortization of acquired intangible assets, stock-based
compensation expense, merger integration expenses, acquisition costs, gains and
losses on equity securities, amortization of incremental costs to obtain a
contract, costs associated with unused office space, and certain other non-
operating items.

• Non-GAAP net income is calculated by adding back to GAAP net income before
income taxes the following items: amortization of acquired intangible assets,
stock-based compensation expense, merger integration expenses, acquisition
costs, gains and losses on equity securities, costs associated with unused
office space, and losses on extinguishment of debt, and subtracting a non-GAAP
tax provision using a normalized non-GAAP tax rate.

• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net
income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared
in accordance with GAAP and should not be considered as a substitute for, or
superior to, GAAP results. We believe that these non-GAAP financial measures
provide useful information to management and investors regarding certain
financial and business trends relating to the Company's financial condition and
results of operations. The Company cautions investors that non-GAAP financial
information, by its nature, departs from GAAP; accordingly, its use can make it
difficult to compare current results with results from other reporting periods
and with the results of other companies. In addition, while amortization of
acquired intangible assets is being excluded from non-GAAP financial measures,
the revenue generated from those acquired intangible assets is not excluded.
Whenever we use these non-GAAP financial measures, we provide a reconciliation
of the applicable non-GAAP financial measure to the most closely applicable GAAP
financial measure. Investors are encouraged to review the related GAAP financial
measures and the reconciliation of the non-GAAP financial measures to their most
directly comparable GAAP financial measure as detailed in the tables below.
                                                                                
  About HealthEquity                                                            
                                                                                
HealthEquity and its subsidiaries administer HSAs and other consumer-directed
benefits for more than 17 million accounts in partnership with employers,
benefits advisors, and health and retirement plan providers who share our
mission to save and improve lives by empowering healthcare consumers. For more
information, visit www.healthequity.com.
                                                                                
  Forward-looking statements                                                    
                                                                                
This press release contains “forward-looking statements” within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of
1995, including but not limited to, statements regarding our industry, business
strategy, plans, goals and expectations concerning our markets and market
position, product expansion, future operations, expenses and other results of
operations, revenue, margins, profitability, acquisition synergies, future
                                       2                                        
efficiencies, tax rates, capital expenditures, liquidity and capital resources
and other financial and operating information. When used in this discussion, the
words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,”
“estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,”
“future” and the negative of these or similar terms and phrases are intended to
identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future
events, results or outcomes. These expectations may or may not be realized.
Although we believe the expectations reflected in the forward-looking statements
are reasonable, we can give you no assurance these expectations will prove to be
correct. Some of these expectations may be based upon assumptions, data or
judgments that prove to be incorrect. Actual events, results and outcomes may
differ materially from our expectations due to a variety of known and unknown
risks, uncertainties and other factors. Although it is not possible to identify
all of these risks and factors, they include, among others, risks related to the
following:

• our ability to adequately place and safeguard our custodial assets, or the
failure of any of our depository or insurance company partners;

• our ability to compete effectively in a rapidly evolving healthcare and
benefits administration industry;

• our dependence on the continued availability and benefits of tax-advantaged
HSAs and other CDBs;

• the impact of fraudulent account activity involving our member accounts or our
third-party service providers on our reputation and financial results;

• our ability to successfully identify, acquire and integrate additional
portfolio purchases or acquisition targets;

• the significant competition we face and may face in the future, including from
those with greater resources than us;

• our reliance on the availability and performance of our technology and
communications systems;

• potential future cybersecurity breaches of our technology and communications
systems and other data interruptions, including resulting costs and liabilities,
reputational damage and loss of business;

• the current uncertain healthcare environment, including changes in healthcare
programs and expenditures and related regulations;

• our ability to comply with current and future privacy, healthcare, tax, ERISA,
investment adviser and other laws applicable to our business;

• our reliance on partners and third-party vendors for distribution and
important services;

• our ability to develop and implement updated features for our technology
platforms and communications systems; and

• our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the
risks detailed in our filings with the Securities and Exchange Commission,
including, without limitation, our Annual Report on Form 10-K for the fiscal
year ended January 31, 2026 and subsequent periodic and current reports. Past
performance is not necessarily indicative of future results. We undertake no
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. Forward-
looking statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
                                                                                
  Investor Relations Contact                                                    
                                                                                
Richard Putnam

801-727-1000

[email protected]
                                       3                                        
                                                                                
  HealthEquity, Inc. and subsidiaries                                           
                                                                                
Condensed consolidated balance sheets
                                                                                
  (in                                                                           
  thousands,                                                                    
  except par                                                    January 31,     
  value)                         July 31, 2026                  2026            
 ────────────────────────────────────────────────────────────────────────────── 
                                 -unaudited                                     
  Assets                                                                        
  Current                                                                       
  assets                                                                        
  Cash and cash    $    256,003                   $    318,927                  
  equivalents                                                                   
  Accounts                                                                      
  receivable,                                                                   
  net of                                                                        
  allowance                                                                     
  for doubtful                                                                  
  accounts of                                                                   
  $1,067 and            122,193                        123,696                  
  $924                                                                          
  as of July                                                                    
  31, 2026 and                                                                  
  January 31,                                                                   
  2026,                                                                         
  respectively                                                                  
  Prepaid                                                                       
  expenses and           82,008                         69,658                  
  other current                                                                 
  assets                                                                        
  Total current         460,204                        512,281                  
  assets                                                                        
  Property and                                                                  
  equipment,              4,823                          3,177                  
  net                                                                           
  Operating                                                                     
  lease                  32,874                         36,310                  
  right-of-use                                                                  
  assets                                                                        
  Intangible          1,047,797                      1,097,172                  
  assets, net                                                                   
  Goodwill            1,648,145                      1,648,145                  
  Other assets           77,520                         83,247                  
  Total assets     $  3,271,363                   $  3,380,332                  
  Liabilities                                                                   
  and                                                                           
  stockholders’                                                                 
  equity                                                                        
  Current                                                                       
  liabilities                                                                   
  Accounts         $      8,592                   $     12,159                  
  payable                                                                       
  Accrued                37,913                         60,392                  
  compensation                                                                  
  Accrued                97,300                         74,388                  
  liabilities                                                                   
  Operating                                                                     
  lease                   9,970                          9,911                  
  liabilities                                                                   
  Total current         153,775                        156,850                  
  liabilities                                                                   
  Long-term                                                                     
  liabilities                                                                   
  Long-term                                                                     
  debt, net of          931,062                        957,379                  
  issuance                                                                      
  costs                                                                         
  Operating                                                                     
  lease                  29,984                         34,190                  
  liabilities,                                                                  
  non-current                                                                   
  Other                                                                         
  long-term              73,999                         31,007                  
  liabilities                                                                   
  Deferred tax           92,433                         93,710                  
  liability                                                                     
  Total                                                                         
  long-term           1,127,478                      1,116,286                  
  liabilities                                                                   
  Total               1,281,253                      1,273,136                  
  liabilities                                                                   
  Commitments                                                                   
  and                                                                           
  contingencies                                                                 
  Stockholders’                                                                 
  equity                                                                        
  Preferred                                                                     
  stock,                                                                        
  $0.0001 par                                                                   
  value,                                                                        
  100,000                                                                       
  shares                                                                        
  authorized,                                                                   
  no shares                   —                              —                  
  issued and                                                                    
  outstanding                                                                   
  as of July                                                                    
  31,                                                                           
  2026 and                                                                      
  January 31,                                                                   
  2026,                                                                         
  respectively                                                                  
  Common stock,                                                                 
  $0.0001 par                                                                   
  value,                                                                        
  900,000                                                                       
  shares                                                                        
  authorized,                                                                   
  82,909 and                                                                    
  85,007                      8                              8                  
  shares issued                                                                 
  and                                                                           
  outstanding                                                                   
  as of July                                                                    
  31, 2026 and                                                                  
  January 31,                                                                   
  2026,                                                                         
  respectively                                                                  
  Additional                                                                    
  paid-in             1,896,571                      1,916,989                  
  capital                                                                       
  Accumulated           162,583                        195,906                  
  earnings                                                                      
  Accumulated                                                                   
  other                 -69,052                         -5,707                  
  comprehensive                                                                 
  loss                                                                          
  Total                                                                         
  stockholders’       1,990,110                      2,107,196                  
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and              $  3,271,363                   $  3,380,332                  
  stockholders’                                                                 
  equity                                                                        
                                                                                
                                       4                                        
                                                                                
  HealthEquity, Inc. and subsidiaries                                           
                                                                                
Condensed consolidated statements of operations (unaudited)
                                                                                
  (in                                                                           
  tho…                                Three                               Six   
  exc…                                mont…                               mon…  
  per                                 ended                               end…  
  sha…                                July                                July  
  dat…                                31,                                 31,   
  Rev…              2026              2025              2026              2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Ser…    $  124,…          $  117,…           $  247…          $  237,…        
  rev…                                                                          
  Cus…       175,…             159,…              350…             316,…        
  rev…                                                                          
  Int…       50,3…             48,0…              107…             102,…        
  rev…                                                                          
  Tot…       350,…             325,…              705…             656,…        
  rev…                                                                          
  Cost                                                                          
  of                                                                            
  rev…                                                                          
  Ser…       73,1…             75,1…              151…             163,…        
  cos…                                                                          
  Cus…       12,0…             11,1…              23,…             21,8…        
  cos…                                                                          
  Int…       7,525             6,947              15,…             14,7…        
  cos…                                                                          
  Tot…                                                                          
  cost       92,7…             93,2…              191…             199,…        
  of                                                                            
  rev…                                                                          
  Gro…       257,…             232,…              514…             456,…        
  pro…                                                                          
  Ope…                                                                          
  exp…                                                                          
  Sal…                                                                          
  and        23,2…             19,9…              50,…             45,9…        
  mar…                                                                          
  Tec…                                                                          
  and        73,9…             64,8…              141…             126,…        
  dev…                                                                          
  Gen…                                                                          
  and        34,8…             29,9…              66,…             55,5…        
  adm…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…       26,2…             27,0…              52,…             54,0…        
  int…                                                                          
  ass…                                                                          
  Mer…         971             1,266              2,0…             2,541        
  int…                                                                          
  Tot…                                                                          
  ope…       159,…             142,…              312…             284,…        
  exp…                                                                          
  Inc…                                                                          
  from       98,6…             89,6…              201…             172,…        
  ope…                                                                          
  Oth…                                                                          
  exp…                                                                          
  Int…       -12,…             -14,…              -25…             -29,…        
  exp…                                                                          
  Oth…                                                                          
  inc…       1,780             3,391              3,8…             6,124        
  net                                                                           
  Tot…                                                                          
  oth…       -10,…             -11,…              -21…             -23,…        
  exp…                                                                          
  Inc…                                                                          
  bef…       87,8…             78,0…              180…             149,…        
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax        22,2…             18,1…              45,…             35,2…        
  pro…                                                                          
  Net     $  65,6…          $  59,8…           $  135…          $  113,…        
  inc…                                                                          
  Net                                                                           
  inc…                                                                          
  per                                                                           
  sha…                                                                          
  Bas…    $   0.79          $   0.69           $  1.61          $   1.31        
  Dil…    $   0.78          $   0.68           $  1.60          $   1.29        
  Wei…                                                                          
  num…                                                                          
  of                                                                            
  sha…                                                                          
  used                                                                          
  in                                                                            
  com…                                                                          
  net                                                                           
  inc…                                                                          
  per                                                                           
  sha…                                                                          
  Bas…       83,3…             86,5…              83,…             86,6…        
  Dil…       84,0…             87,7…              84,…             88,1…        
                                                                                
                                       5                                        
                                                                                
  HealthEquity, Inc. and subsidiaries                                           
                                                                                
Condensed consolidated statements of comprehensive income (unaudited)
                                                                                
                                      Thr…                               Six    
                                      mon…                               mont…  
                                      end…                               ended  
                                      July                               July   
  (in                                 31,                                31,    
  tho…              2026              2025              2026             2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $  65,6…          $  59,8…          $  135,…          $  113…         
  inc…                                                                          
  Oth…                                                                          
  com…                                                                          
  inc…                                                                          
  (lo…                                                                          
  Cash                                                                          
  flow                                                                          
  hed…                                                                          
  Net                                                                           
  unr…       -37,…               203             -63,…              203         
  gai…                                                                          
  (lo…                                                                          
  Rec…                                                                          
  of                                                                            
  net                                                                           
  (ga…                                                                          
  los…          22                 —              -126                —         
  inc…                                                                          
  in                                                                            
  net                                                                           
  inc…                                                                          
  Net                                                                           
  cha…                                                                          
  net                                                                           
  of                                                                            
  inc…                                                                          
  tax                                                                           
  ben…                                                                          
  (ex…       -37,…               203             -63,…              203         
  of                                                                            
  $12…                                                                          
  $(7…                                                                          
  $20…                                                                          
  and                                                                           
  $(7…                                                                          
  res…                                                                          
  Tot…                                                                          
  oth…                                                                          
  com…       -37,…               203             -63,…              203         
  inc…                                                                          
  (lo…                                                                          
  Com…    $  28,3…          $  60,0…          $  71,7…          $  113…         
  inc…                                                                          
                                                                                
                                       6                                        
                                                                                
  HealthEquity, Inc. and subsidiaries                                           
                                                                                
Condensed consolidated statements of cash flows (unaudited)
                                                                                
  (in thousands)                                                                
  Cash flows from                                         Six months ended      
  operating                                               July 31,              
  activities:                        2026                 2025                  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income            $   135,062          $   113,769                        
  Adjustments to                                                                
  reconcile net                                                                 
  income to                                                                     
  net cash provided                                                             
  by operating                                                                  
  activities:                                                                   
  Depreciation and           80,169               77,195                        
  amortization                                                                  
  Stock-based                41,616               33,404                        
  compensation                                                                  
  Amortization of                                                               
  debt discount and             558                  533                        
  issuance costs                                                                
  Amortization of                                                               
  gains on                     -168                    —                        
  derivatives                                                                   
  Deferred taxes             19,321               30,711                        
  Changes in                                                                    
  operating assets                                                              
  and                                                                           
  liabilities:                                                                  
  Accounts                    1,503                6,842                        
  receivable, net                                                               
  Prepaid expenses                                                              
  and other current         -12,581              -20,650                        
  and                                                                           
  non-current assets                                                            
  Operating lease                                                               
  right-of-use                3,436                3,339                        
  assets                                                                        
  Accrued                   -21,095              -35,032                        
  compensation                                                                  
  Accounts payable,                                                             
  accrued                                                                       
  liabilities,              -13,595               -3,785                        
  and other current                                                             
  liabilities                                                                   
  Operating lease                                                               
  liabilities,               -4,206               -3,951                        
  non-current                                                                   
  Other long-term             3,665               -1,771                        
  liabilities                                                                   
  Net cash provided                                                             
  by operating              233,685              200,604                        
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Capitalized                                                                   
  software                  -30,720              -26,464                        
  development costs                                                             
  Purchases of                                                                  
  property and               -1,340                 -859                        
  equipment                                                                     
  Settlement of              -7,759                    —                        
  derivatives, net                                                              
  Net cash used in                                                              
  investing                 -39,819              -27,323                        
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Repurchases of           -231,054             -125,810                        
  common stock                                                                  
  Principal payments        -26,875              -50,000                        
  on long-term debt                                                             
  Settlement of                                                                 
  client-held funds             480                  596                        
  obligation, net                                                               
  Proceeds from                                                                 
  exercise of common            659               10,446                        
  stock                                                                         
  options                                                                       
  Net cash used in                                                              
  financing                -256,790             -164,768                        
  activities                                                                    
  Increase                                                                      
  (decrease) in cash        -62,924                8,513                        
  and cash                                                                      
  equivalents                                                                   
  Beginning cash and        318,927              295,948                        
  cash equivalents                                                              
  Ending cash and       $   256,003          $   304,461                        
  cash equivalents                                                              
                                                                                
                                       7                                        
                                                                                
  HealthEquity, Inc. and subsidiaries                                           
                                                                                
Condensed consolidated statements of cash flows (unaudited) (continued)
                                                                                
  (in thousands)                                        Six months ended July   
  Supplemental cash                                     31,                     
  flow data:                         2026               2025                    
 ────────────────────────────────────────────────────────────────────────────── 
  Interest expense        $  23,350          $  28,362                          
  paid in cash                                                                  
  Income tax payments,       35,586              6,507                          
  net                                                                           
  Supplemental                                                                  
  disclosures of                                                                
  non-cash                                                                      
  investing and                                                                 
  financing                                                                     
  activities:                                                                   
  Capitalized software                                                          
  development costs                                                             
  included in accounts        3,434              3,380                          
  payable, accrued                                                              
  liabilities, or                                                               
  accrued compensation                                                          
  Purchases of                                                                  
  property and                                                                  
  equipment                   1,294                155                          
  included in accounts                                                          
  payable or accrued                                                            
  liabilities                                                                   
  Repurchases of                                                                
  common stock                3,255              1,246                          
  included in                                                                   
  accrued liabilities                                                           
  Exercise of common                                                            
  stock options                  57                  —                          
  receivable                                                                    
                                                                                
                                                                                
  Stock-based compensation expense (unaudited)                                  
                                                                                
Total stock-based compensation expense included in the condensed consolidated
statements of operations and comprehensive income is as follows:
                                                                                
                                      Thr…                               Six    
                                      mon…                               mont…  
                                      end…                               ended  
                                      July                               July   
  (in                                 31,                                31,    
  tho…              2026              2025              2026             2025   
 ────────────────────────────────────────────────────────────────────────────── 
  Cost                                                                          
  of      $  2,713          $  3,114          $  5,500          $  6,5…         
  rev…                                                                          
  Sal…                                                                          
  and        3,229             1,529             7,753             6,3…         
  mar…                                                                          
  Tec…                                                                          
  and        6,178             5,732             10,1…             11,…         
  dev…                                                                          
  Gen…                                                                          
  and        10,0…             8,693             18,2…             8,8…         
  adm…                                                                          
  Tot…                                                                          
  sto…    $  22,2…          $  19,0…          $  41,6…          $  33,…         
  com…                                                                          
  exp…                                                                          
                                                                                
Total Accounts (unaudited)
                                                                                
  (in                                                                           
  thous…            July              July                             January  
  except            31,               31,            %                 31,      
  perce…            2026              2025           Change            2026     
 ────────────────────────────────────────────────────────────────────────────── 
  HSAs      10,739             9,989              8  %         10,570           
  New                                                                           
  HSAs                                                                          
  from         202               163             24  %            553           
  sales                                                                         
  -                                                                             
  Quart…                                                                        
  New                                                                           
  HSAs                                                                          
  from         374               312             20  %          1,040           
  sales                                                                         
  -                                                                             
  Year-…                                                                        
  New                                                                           
  HSAs                                                                          
  from           —                 —                 *              —           
  acqui…                                                                        
  -                                                                             
  Year-…                                                                        
  HSAs                                                                          
  with         939               782             20  %            832           
  inves…                                                                        
  CDBs       7,016             7,153             -2  %          7,221           
  Total     17,755            17,142              4  %         17,791           
  Accou…                                                                        
  Avera…                                                                        
  Total                                                                         
  Accou…    17,710            17,044              4  %         17,462           
  -                                                                             
  Quart…                                                                        
  Avera…                                                                        
  Total                                                                         
  Accou…    17,772            17,083              4  %         17,220           
  -                                                                             
  Year-…                                                                        
                                                                                
* Not meaningful

HSA Assets (unaudited)
                                                                                
  (in                                                                           
  mil…              July               July                              Janu…  
  exc…              31,                31,           %                   31,    
  per…              2026               2025          Chan…               2026   
 ────────────────────────────────────────────────────────────────────────────── 
  HSA     $  17,3…           $  17,0…             2  %        $  17,982         
  cash                                                                          
  HSA        20,5…              16,1…            28  %           18,482         
  inv…                                                                          
  Tot…                                                                          
  HSA        37,9…              33,1…            14  %           36,464         
  Ass…                                                                          
  Ave…                                                                          
  dai…                                                                          
  HSA        17,3…              17,0…             2  %           17,090         
  cash                                                                          
  -                                                                             
  Qua…                                                                          
  Ave…                                                                          
  dai…                                                                          
  HSA        17,5…              17,1…             2  %           17,082         
  cash                                                                          
  -                                                                             
  Yea…                                                                          
                                                                                
                                       8                                        
                                                                                
  HSA cash maturity schedule                                                    
                                                                                
The following table summarizes the amount of HSA cash held by our depository
partners and insurance company partners that is expected to reprice by fiscal
year and the respective average annualized yield currently earned on that HSA
cash as of July 31, 2026:
                                                                                
  Year ending                                                                   
  January 31, (in                                                               
  billions, except                                         Average annualized   
  percentages)                   HSA cash expected         yield                
  Remainder of 2027         2.3  to reprice           1.5  %                    
 ────────────────────────────────────────────────────────────────────────────── 
  2028                      2.5                       4.0  %                    
  2029                      1.8                       3.8  %                    
  2030                      2.3                       4.4  %                    
  Thereafter                7.8                       4.4  %                    
  Total (1)             $  16.7                       3.9  %                    
                                                                                
(1) Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July
31, 2026.

Client-held funds (unaudited)
                                                                                
  (in                                                                           
  mill…            July              July                              January  
  exce…            31,               31,           %                   31,      
  perc…            2026              2025          Change              2026     
 ────────────────────────────────────────────────────────────────────────────── 
  Clie…    $  931            $  818            14  %         $  1,090           
  funds                                                                         
  Aver…                                                                         
  daily                                                                         
  Clie…       936               884             6  %              879           
  funds                                                                         
  -                                                                             
  Quar…                                                                         
  Aver…                                                                         
  daily                                                                         
  Clie…       986               893            10  %              864           
  funds                                                                         
  -                                                                             
  Year…                                                                         
                                                                                
Reconciliation of net income to Adjusted EBITDA (unaudited)
                                                                                
                                      Three                               Six   
                                      mont…                               mon…  
                                      ended                               end…  
                                      July                                July  
  (in                                 31,                                 31,   
  tho…              2026              2025              2026              2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $  65,6…          $  59,8…           $  135…          $  113,…        
  inc…                                                                          
  Int…       -1,7…             -3,3…              -3,…             -6,0…        
  inc…                                                                          
  Int…       12,6…             14,9…              25,…             29,8…        
  exp…                                                                          
  Inc…                                                                          
  tax        22,2…             18,1…              45,…             35,2…        
  pro…                                                                          
  Dep…                                                                          
  and        15,6…             11,4…              27,…             23,1…        
  amo…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…       26,2…             27,0…              52,…             54,0…        
  int…                                                                          
  ass…                                                                          
  Sto…                                                                          
  com…       22,2…             19,0…              41,…             33,4…        
  exp…                                                                          
  Mer…                                                                          
  int…         971             1,266              2,0…             2,541        
  exp…                                                                          
  Amo…                                                                          
  of                                                                            
  inc…                                                                          
  cos…       2,139             1,951              4,2…             3,877        
  to                                                                            
  obt…                                                                          
  a                                                                             
  con…                                                                          
  Cos…                                                                          
  ass…                                                                          
  with       1,016               723              1,7…             1,575        
  unu…                                                                          
  off…                                                                          
  spa…                                                                          
  Oth…         -20               -27              -181               -27        
  Adj…    $  166,…          $  151,…           $  331…          $  291,…        
  EBI…                                                                          
                                                                                
Net income and Adjusted EBITDA as a percentage of revenue (unaudited)
                                                                                
                       …                                     …                  
                       …                                     …                  
                       …                                     …                  
                       …                                     …                  
                       …          $       %                  …                  
            …          …          …       …                  …                  
 ────────────────────────────────────────────────────────────────────────────── 
      $  …       $  …       $  …       …  %      …      $           …      …    
         …  %       …  %                         …           %                  
      $  …       $  …       $  …       …  %      …      $           …      …    
         …  %       …  %                         …           %                  
                                                                                
                                       9                                        
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
                                                                                
                                                   Outlook for the year ending  
  (in millions)                                               January 31, 2027  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                                                        $242 - 248  
  Interest income                                                           -7  
  Interest expense                                                          50  
  Income tax provision                                                 81 - 83  
  Depreciation and amortization                                             54  
  Amortization of acquired intangible assets                               104  
  Stock-based compensation expense                                          87  
  Merger integration expenses                                                5  
  Amortization of incremental costs to obtain a                              9  
  contract                                                                      
  Costs associated with unused office space                                  3  
  Adjusted EBITDA                                                   $628 - 636  
                                                                                
Note: Values presented may not calculate due to rounding.

Reconciliation of net income to non-GAAP net income (unaudited)
                                                                                
  (in                                 Three                               Six   
  tho…                                mont…                               mon…  
  exc…                                ended                               end…  
  per                                 July                                July  
  sha…                                31,                                 31,   
  dat…              2026              2025              2026              2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $  65,6…          $  59,8…           $  135…          $  113,…        
  inc…                                                                          
  Inc…                                                                          
  tax        22,2…             18,1…              45,…             35,2…        
  pro…                                                                          
  Inc…                                                                          
  bef…                                                                          
  inc…       87,8…             78,0…              180…             149,…        
  tax…                                                                          
  -                                                                             
  GAAP                                                                          
  Non…                                                                          
  adj…                                                                          
  Amo…                                                                          
  of                                                                            
  acq…       26,2…             27,0…              52,…             54,0…        
  int…                                                                          
  ass…                                                                          
  Sto…                                                                          
  com…       22,2…             19,0…              41,…             33,4…        
  exp…                                                                          
  Mer…                                                                          
  int…         971             1,266              2,0…             2,541        
  exp…                                                                          
  Cos…                                                                          
  ass…                                                                          
  with       1,016               723              1,7…             1,575        
  unu…                                                                          
  off…                                                                          
  spa…                                                                          
  Tot…                                                                          
  adj…                                                                          
  to                                                                            
  inc…                                                                          
  bef…       50,4…             48,0…              98,…             91,5…        
  inc…                                                                          
  tax…                                                                          
  -                                                                             
  GAAP                                                                          
  Inc…                                                                          
  bef…                                                                          
  inc…       138,…             126,…              278…             240,…        
  tax…                                                                          
  -                                                                             
  Non…                                                                          
  Inc…                                                                          
  tax                                                                           
  pro…       34,5…             31,5…              69,…             60,1…        
  -                                                                             
  Non…                                                                          
  (1)                                                                           
  Non…                                                                          
  net        103,…             94,5…              208…             180,…        
  inc…                                                                          
  Dil…                                                                          
  wei…       84,0…             87,7…              84,…             88,1…        
  sha…                                                                          
  GAAP                                                                          
  net                                                                           
  inc…    $   0.78          $   0.68           $  1.60          $   1.29        
  per                                                                           
  dil…                                                                          
  sha…                                                                          
  Non…                                                                          
  net                                                                           
  inc…    $   1.24          $   1.08           $  2.47          $   2.05        
  per                                                                           
  dil…                                                                          
  sha…                                                                          
                                                                                
(1) The Company utilizes a normalized non-GAAP tax rate to provide better
consistency across the interim reporting periods within a given fiscal year by
eliminating the effects of non-recurring and period-specific items, which can
vary in size and frequency, and which are not necessarily reflective of the
Company’s longer-term operations. The normalized non-GAAP tax rate applied to
each period presented was 25%. The Company may adjust its non-GAAP tax rate as
additional information becomes available and in conjunction with any other
significant events occurring that may materially affect this rate, such as
merger and acquisition activity, changes in business outlook, or other changes
in expectations regarding tax regulations.
                                       10                                       
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
                                                                                
                                                   Outlook for the year ending  
  (in millions, except per share data)                        January 31, 2027  
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                                                        $242 - 248  
  Income tax provision                                                 81 - 83  
  Income before income taxes - GAAP                                  323 - 331  
  Non-GAAP adjustments:                                                         
  Amortization of acquired intangible assets                               104  
  Stock-based compensation expense                                          87  
  Merger integration expenses                                                5  
  Costs associated with unused office space                                  3  
  Total adjustments to income before income                                     
  taxes -                                                                  199  
  GAAP                                                                          
  Income before income taxes - Non-GAAP                              522 - 530  
  Income tax provision - Non-GAAP (1)                                131 - 133  
  Non-GAAP net income                                               $392 - 398  
  Diluted weighted-average shares                                           84  
  GAAP net income per diluted share                               $2.88 - 2.96  
  Non-GAAP net income per diluted share                           $4.66 - 4.73  
                                                                                
Note: Values presented may not calculate due to rounding.

(1) The Company utilizes a normalized non-GAAP tax rate to provide better
consistency across the interim reporting periods within a given fiscal year by
eliminating the effects of non-recurring and period-specific items, which can
vary in size and frequency, and which are not necessarily reflective of the
Company’s longer-term operations. The normalized non-GAAP tax rate applied to
each period presented was 25%. The Company may adjust its non-GAAP tax rate as
additional information becomes available and in conjunction with any other
significant events occurring that may materially affect this rate, such as
merger and acquisition activity, changes in business outlook, or other changes
in expectations regarding tax regulations.
                                       11                                       
                                                                                
  Certain terms                                                                 
                                                                                
                                                                                
  Term                                   Definition                             
                                         Health Savings Account, which is a     
                                         financial account through which        
  HSA                                    consumers spend and save long-term     
                                         for healthcare on a tax-advantaged     
                                         basis.                                 
                                         Consumer-directed benefits offered by  
                                         employers, including flexible          
                                         spending and health reimbursement      
  CDB                                    arrangements (“FSAs” and “HRAs”),      
                                         Consolidated Omnibus Budget            
                                         Reconciliation Act (“COBRA”)           
                                         administration, commuter and other     
                                         benefits.                              
  HSA member                             Consumers with HSAs that we serve.     
                                         HSA members’ custodial cash assets     
                                         held by our federally insured          
                                         depository partners and our insurance  
  Total HSA Assets                       company partners. Total HSA Assets     
                                         also includes HSA members'             
                                         investments held by our custodial      
                                         investment fund partner.               
  Client                                 Our employer clients.                  
  Total Accounts                         The sum of HSAs and CDBs on our        
                                         platforms.                             
                                         Deposits held on behalf of our         
  Client-held funds                      Clients to facilitate administration   
                                         of our CDBs.                           
                                         Our health plan partners, benefits     
  Network Partner                        administrators, and retirement plan    
                                         recordkeepers.                         
                                         Earnings before interest, taxes,       
                                         depreciation and amortization,         
                                         amortization of acquired intangible    
                                         assets, stock-based compensation       
                                         expense, merger integration expenses,  
  Adjusted EBITDA                        acquisition costs, gains and losses    
                                         on equity securities, amortization of  
                                         incremental costs to obtain a          
                                         contract, costs associated with        
                                         unused office space, and certain       
                                         other non-operating items.             
                                         Calculated by adding back to GAAP net  
                                         income before income taxes the         
                                         following items: amortization of       
                                         acquired intangible assets,            
                                         stock-based compensation expense,      
                                         merger integration expenses,           
  Non-GAAP net income                    acquisition costs, gains and losses    
                                         on equity securities, costs            
                                         associated with unused office space,   
                                         and losses on extinguishment of debt,  
                                         and subtracting a non-GAAP tax         
                                         provision using a normalized non-GAAP  
                                         tax rate.                              
  Non-GAAP net income per diluted        Calculated by dividing non-GAAP net    
  share                                  income by diluted weighted-average     
                                         shares outstanding.                    
                                                                                
                                       12                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HQY/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.